Drug Profile
Research programme: therapeutic antibodies - Dyax/Organon
Latest Information Update: 25 Jan 2010
Price :
$50
*
At a glance
- Originator Dyax; Organon
- Developer Dyax; Schering-Plough
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer
Most Recent Events
- 19 Nov 2007 Organon has been acquired and merged into Schering-Plough
- 19 Jul 2007 Preclinical trials in Autoimmune disorders in Netherlands (Parenteral)
- 19 Jul 2007 Preclinical trials in Cancer in Netherlands (Parenteral)